Table 2 Clinical trials of histone deacetylase inhibitors in viral infections and viral-associated malignancies
From: Control of viral infections by epigenetic-targeted therapy
Drug | Combination | Indication | Clinical result | Study phase and status | Trial* | Reference |
|---|---|---|---|---|---|---|
Panobinostat | Antiretroviral therapy | HIV infection | -Increase in unspliced HIV RNA -No reduction in integrated HIV DNA -Safe, well tolerated | Phases I–II | NCT01680094 | [195] |
-Antiretroviral therapy -Interferon-alpha2a | HIV infection | Ongoing | Phases I–II | NCT02471430 | ||
Vorinostat | Antiretroviral therapy | HIV infection | -Increase in cell-associated HIV RNA with no effective depletion of persistent HIV reservoir -Safe, well tolerated | Phases I–II | NCT01319383 | [196] |
-Antiretroviral therapy -Autologous dendritic cell vaccine (AGS 004) | HIV infection | No published results yet | Phase I | NCT02707900 | ||
-Antiretroviral therapy -Disulfiram | HIV infection | Suspended | Phases I–II | NCT03198559 | ||
Romidepsin | Antiretroviral therapy | HIV infection | -Increase in cell-associated un-spliced HIV-1 RNA -No effect on the number of HIV-specific T cells -No severe adverse events | Phases I–II | NTC02092116 | [197] |
Antiretroviral therapy | HIV infection | No published results yet | Phases I–II | NCT01933594 | ||
MVA.HIVconsv vaccine | HIV infection | No published results yet | Phase I | NCT02616874 | ||
Broadly neutralizing antibody (3BNC117) | HIV infection | Ongoing | Phase II | NCT03041012 | ||
Valproic acid | Antiretroviral therapy | HIV infection | No significant reductions in the frequency of CD4+ T cells harboring replication-competent HIV | Phase II | NCT00289952 | [198] |
Belinostat | None | Unresectable hepatocellular carcinoma | -Tumor stabilization -Well tolerated | Phases I–II | NCT00321594 | [200] |
Mocetinostat | None | Relapsed and refractory classical Hodgkin lymphoma | -Decrease in tumor measurements -Grade 3 and 4 adverse events (neutropenia and pneumonia) | Phase II | NCT00358982 | [201] |
Tractinostat | Valganciclovir | EBV-associated lymphoid malignancies | Ongoing | Phase Ib/II | NCT03397706 |